Insulin glargine 300 U/mL is a novel glargine formulation which shows slower and more prolonged absorption following subcutaneous administration in comparison to insulin glargine 100 U/mL

We evaluated the effectiveness and safety of insulin glargine 300 U/mL in patients with type 2 diabetes mellitus previously inadequately controlled with different basal or premix insulin therapy regimes

The primary objective was to assess the change in glycated hemoglobin level from day of the insulin glargine 300 U/mL initiation to the end of the observational period

There was a significant reduction in glycated hemoglobin level at each visit compared to the previous visit accompanied by significant reduction of all hypoglycemic events

Initiation of insulin glargine 300 U/mL therapy significantly improved glycemic control and reduced the risk of hypoglycemia in patients with type 2 diabetes mellitus inadequately controlled with different basal or premix insulin therapy regimes